Celldex Therapeutics new Trading Buy in STI Medical Profits Portfolio

[from today’s edition of Smart Tech 50 Weekly Movers]

Celldex Therapeutics (CLDX) is almost an EBIS stock. The company is working on a vaccine for aggressive brain cancers. It has plenty of money on its balance sheet but is high risk and has not been able to make money consistently. In this market, it may be worth exploring on a trading basis with a buy limit of $14 and stop loss at $10.

 

Stock Talk

Add New Comments

You must be logged in to post to Stock Talk OR create an account